您的位置：首页 > 产品中心 > 461432-26-8， Dapagliflozin
Dapagliflozin
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4086688 | 5 MG | 1140 | |||
| 4086688 | 25 MG | 4200 |
产品别名
461432-26-8
Dapagliflozin
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol
BMS 512148
BMS-512148
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C21H25ClO6 |
| Molecular weight | 408.87 |
| MDL number | MFCD13182359 |
| Biochem/physiol Actions【生化/生理作用】 | Dapagliflozin (BMS-512148) is an orally active, potent and selective renal sodium-dependent glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor (human/rat SGLT2 IC50 = 1.1/3 nM vs. human/rat SGLT1 IC50 = 1.39/0.6 μM; R-methyl-D-glucopyranoside (AMG) uptake assay with respective CHO transfectants). Dapagliflozin reduces blood glucose levels (by 55% in streptozotocin (STZ)-induced hyperglycemic rats 5 hrs post 0.1 mg/kg p.o.) by preventing the renal glucose reabsorption process and promoting glucose excretion in urine with good pharmacokinetic properties and oral availability (84% in rats and 83% in dogs, respectively, post 1 mg/kg and 6.6 mg/kg p.o.) in vivo. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to beige |
| solubility【溶解性】 | DMSO: 2 mg/mL, clear |
| storage temp.【储存温度】 | −20℃ |
| SMILES string | CCOC1=CC=C(C=C1)CC2=C(C=CC([C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)=C2)Cl |
安全信息
| Pictograms【象形图】 | GHS07,GHS08,GHS09 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H302 - H319 - H372 - H411 |
| Precautionary Statements | P260 - P264 - P273 - P301 + P312 - P305 + P351 + P338 - P314 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - STOT RE 1 |
| Target Organs【靶器官】 | Kidney |
| Storage Class Code【储存分类代码】 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
